Highly prognostic signature for stage II colon cancer from the TOSCA trial: The PROSIT study.

• DOI: 10.1200/jco.2024.42.16_suppl.3524
• Publication Date: 2024-06-04T20:26:26Z
• Authors: Alberto Puccini; Lorenzo Ferrando; Luca Mazzarella; Gianmaria Frige; Anna Maria Pessino; Alessandro Pastorino; Valentino Martelli; Anna Garuti; Veronica Di Antonio; Alberto Ballestrero; Valter Torri; Roberto Labianca; Matteo Fassan; Sara Lonardi; Gabriele Zoppoli; Alberto F. Sobrero
• Keywords: 03 medical and health sciences; 0302 clinical medicine

3524 Background: The predictive and prognostic value of current biomarkers for guiding the treatment stage II colon cancer (CC) is very limited. Here, we aimed to develop a transcriptional signature high-risk CC patients undergoing adjuvant with either 3 or 6 months FOLFOX4/CAPOX within framework phase III TOSCA Italian trial. Methods: We conducted an observational retrospective study based on trial database, matching 62 who relapsed did not. criteria included center recruitment, pT stage, type duration (3 months). Transcriptome sequencing was performed material from centrally assessed FFPE blocks Illumina Novaseq 6000 instrument. Generated data were processed using nf-core/rnaseq (v 3.14.0) pipeline, aligned human genome GRCh37/hg19, analyzed differential gene expression, requiring minimum absolute log fold change 1 false discovery rate below 0.1. Enrichment analysis GSVA package z-score method. Results: Out 124 cases considered present analysis, 60% received 40% chemotherapy. median age 64 years (IQR 55.2-71.1), cancers being right-sided. Fifty-seven percent FOLFOX, while remaining treated XELOX. Of matched samples, 72 sufficient quality RNA-seq.We identified among top 17 differentially expressed genes (absolute fold-change > 1, p-value < 0.001, FDR 0.1, see Table). Patients exhibiting lower (PROSIT-L) showed worse disease-free survival (DFS) compared those high (PROSIT-H) (HR 3.5; 95% CI 1.53 – 7.9; p = 0.002), indicating its strong independent value, regardless received. Conclusions: new transcriptomic may help in identifying are likely relapse despite receiving oxaliplatin-based treatment. [Table: text]